Innate immune landscape in glioblastoma patient tumors

February 25, 2016

Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might be effective in this devastating malignancy. Myeloid-derived innate immune cells, such as macrophages, microglia, and myeloid-derived suppressor cells, are known to be present within glioblastomas.

Previous work suggested that the tumor microenvironment triggers microglia and macrophages to polarize to a cell state that dampens responses to tumors; however, there has been only a limited assessment of the immune cell populations in patient tumors.

In this month's issue of JCI Insight, Amy Heimberger and colleagues at the University of Texas MD Anderson Cancer Center provide a comprehensive analysis of myeloid lineage immune cells in the circulation and in tumors of glioblastoma patients.

Their extensive survey relied on immune phenotyping, whole genome microarray analysis, and microRNA expression profiling to characterize myeloid cells in surgical samples from 43 patients.

Their results surprisingly indicated that glioblastoma-associated myeloid cells were most similar to non-polarized cells. Importantly, these findings suggest that strategies to stimulate myeloid to assume an anti- identity may be possible and merit future exploration.

Explore further: Scientists show how cancerous cells evade a potent targeted therapy

More information: Konrad Gabrusiewicz et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype, JCI Insight (2016). DOI: 10.1172/jci.insight.85841

Related Stories

Immune cells link pregnancy and tumor spread

June 6, 2011

Individuals with cancer often do not die as a result of their initial tumor but as a result of tumors at distant sites that are derived from the initial tumor. Pregnancy is a condition that seems to be permissive for tumor ...

Immune cells in lung cancer offer new drug targets

July 16, 2015

Lung cancers attract circulating immune cells to the tumor mass, where the cancer reprograms them to support its growth and progression, researchers from Weill Cornell Medical College have found.

Recommended for you

Discovery of genetic mutation may boost cancer therapies

February 24, 2017

A newly discovered type of genetic mutation that occurs frequently in cancer cells may provide clues about the disease's origins and offer new therapeutic targets, according to research from Weill Cornell Medicine and the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.